Results 201 to 210 of about 97,027 (306)

Clinical Outcome Assessments in Parkinson's Disease: A Scoping Review of Current Rating Scales and Future Needs

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Clinical outcome assessments (COAs) are essential for evaluating symptom severity, treatment response, and disease progression in Parkinson's disease (PD). As clinical knowledge evolves, it is necessary to revisit the recommendation status on the COAs to ensure their continued relevance and validity. Objectives To provide an updated
Evita Papathoma   +14 more
wiley   +1 more source

Patient‐Reported Communication Decline Following Deep Brain Stimulation in Parkinson's Disease

open access: yesMovement Disorders Clinical Practice, EarlyView.
Abstract Background Objective decline in communication abilities following Deep Brain Stimulation (DBS) in People with Parkinson's disease (PwP) is common; however, patient perspectives remain under‐investigated. Objectives This study examined subjective change in communicative efficacy using the Communicative Participation Item Bank (CPIB) in PwP ...
Stephanie M. Simone   +2 more
wiley   +1 more source

Cannabidiol sensitizes triple-negative breast cancer cells to NK cell-mediated killing via EGFR inhibition and FAS upregulation. [PDF]

open access: yesJ Cannabis Res
Garunyapakun P   +5 more
europepmc   +1 more source

Circadian Immunity and Vascular Inflammation in Cardiovascular Disease Chronotherapy Windows: Time for a Re‐Assessment

open access: yesMed Research, EarlyView.
ABSTRACT Circadian rhythms orchestrate cardiovascular physiology by regulating immune and inflammatory pathways. Disruption of these rhythms profoundly alters vascular homeostasis, thereby promoting the onset and progression of cardiovascular diseases (CVD).
Tian Zhang   +22 more
wiley   +1 more source

Effect on Dyskinesia of the Early Combination of Amantadine to Levodopa‐Therapy in Parkinson's Disease: A Randomized, Placebo‐Controlled Study (PREMANDYSK)

open access: yesMovement Disorders, EarlyView.
Abstract Objective Investigate the efficacy of immediate‐release (IR) amantadine in reducing the risk of peak‐dose dyskinesia in early Parkinson's disease (PD) as add‐on to levodopa. Background While the use of amantadine to manage dyskinesia in PD is well supported by controlled clinical trials, data on its efficacy in patients without motor ...
Olivier Rascol   +106 more
wiley   +1 more source

Increased Tumor Necrosis Factor Superfamily Members in Neuroinflammatory Schizophrenia and Bipolar Disorder Midbrains. [PDF]

open access: yesBiol Psychiatry Glob Open Sci
Mendez-Victoriano G   +16 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy